Idiopathic Pulmonary Fibrosis
"Idiopathic Pulmonary Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.
| Descriptor ID |
D054990
|
| MeSH Number(s) |
C08.381.483.487.500 C08.381.765.500
|
| Concept/Terms |
Idiopathic Pulmonary Fibrosis- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibroses
- Pulmonary Fibroses, Idiopathic
- Familial Idiopathic Pulmonary Fibrosis
- Fibrocystic Pulmonary Dysplasia
- Dysplasia, Fibrocystic Pulmonary
- Dysplasias, Fibrocystic Pulmonary
- Fibrocystic Pulmonary Dysplasias
- Pulmonary Dysplasia, Fibrocystic
- Pulmonary Dysplasias, Fibrocystic
- Fibrosing Alveolitis, Cryptogenic
- Hamman-Rich Disease
- Disease, Hamman-Rich
- Diseases, Hamman-Rich
- Hamman Rich Disease
- Hamman-Rich Diseases
- Interstitial Pneumonitis, Usual
- Interstitial Pneumonitides, Usual
- Pneumonitides, Usual Interstitial
- Pneumonitis, Usual Interstitial
- Usual Interstitial Pneumonitides
- Usual Interstitial Pneumonitis
- Pulmonary Fibrosis, Idiopathic
- Usual Interstitial Pneumonia
- Interstitial Pneumonia, Usual
- Interstitial Pneumonias, Usual
- Usual Interstitial Pneumonias
- Idiopathic Fibrosing Alveolitis, Chronic Form
- Cryptogenic Fibrosing Alveolitis
- Cryptogenic Fibrosing Alveolitides
- Fibrosing Alveolitides, Cryptogenic
- Idiopathic Pulmonary Fibrosis, Familial
|
Below are MeSH descriptors whose meaning is more general than "Idiopathic Pulmonary Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Idiopathic Pulmonary Fibrosis".
This graph shows the total number of publications written about "Idiopathic Pulmonary Fibrosis" by people in this website by year, and whether "Idiopathic Pulmonary Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 1 | 4 |
| 2011 | 3 | 1 | 4 |
| 2012 | 4 | 1 | 5 |
| 2013 | 3 | 2 | 5 |
| 2014 | 9 | 2 | 11 |
| 2015 | 4 | 0 | 4 |
| 2016 | 5 | 1 | 6 |
| 2017 | 6 | 0 | 6 |
| 2018 | 5 | 1 | 6 |
| 2019 | 6 | 0 | 6 |
| 2020 | 9 | 2 | 11 |
| 2021 | 10 | 1 | 11 |
| 2022 | 13 | 0 | 13 |
| 2023 | 16 | 0 | 16 |
| 2024 | 6 | 0 | 6 |
| 2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Idiopathic Pulmonary Fibrosis" by people in Profiles.
-
eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2025 Oct; 73(4):572-585.
-
Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models. Nat Commun. 2025 Aug 02; 16(1):7099.
-
Calcium-Sensing Receptor as a Novel Target for the Treatment of Idiopathic Pulmonary Fibrosis. Biomolecules. 2025 Apr 01; 15(4).
-
Influence of lung extracellular matrix from non-IPF and IPF donors on primary human lung fibroblast biology. Biomater Sci. 2025 Mar 25; 13(7):1721-1741.
-
Lung cell transplantation for pulmonary fibrosis. Sci Adv. 2024 08 23; 10(34):eadk2524.
-
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. Am J Respir Crit Care Med. 2024 Aug 15; 210(4):401-423.
-
Aging-Associated Metabolite Methylmalonic Acid Increases Susceptibility to Pulmonary Fibrosis. Am J Pathol. 2024 08; 194(8):1478-1493.
-
Plausible role of INPP4A dysregulation in idiopathic pulmonary fibrosis. Physiol Rep. 2024 May; 12(9):e16032.
-
Alveolar Epithelial Cell Dysfunction in Idiopathic Pulmonary Fibrosis Linked to Lipid Alterations: Therapeutic Implications. Am J Respir Cell Mol Biol. 2024 Apr; 70(4):233-234.
-
Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis. BMC Pulm Med. 2024 Mar 20; 24(1):143.